Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wristband could change how we track high blood pressure

NCT ID NCT06356077

Knowledge-focused Sponsor: Aktiia SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study looked at how blood pressure changes over 12 weeks in 1,729 adults with hypertension who used the Aktiia 24/7 optical blood pressure monitor. The device is a wristband that measures blood pressure continuously without a cuff. Researchers also asked participants which monitoring method they preferred: the Aktiia bracelet, a home blood pressure monitor, or a 24-hour ambulatory monitor. The goal was to gather information, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aktiia 24/7 optical blood pressure monitoring (OBPM) device
What this could lead to
If successful, this study could show that continuous optical blood pressure monitoring is a practical and preferred way to track hypertension at home.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove that using the device improves health outcomes, and results may not apply to all people with high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,729 people

The number who actually took part.

Started

Jul 2024

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The final study population should cover the following phenotypes: * Close to 50% females and 50% males, * At least 20% of non-Caucasian participants, * At least 20% of participants with Systolic Blood Pressure (SBP) ≥150mmHg (assessed at baseline via the study device).

Ages

21 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult participants aged 22 to 85 years old 2. A participant whose last blood pressure reading was within the last 12 months and was either: 1. SBP ≥145 2. or ≥DBP 90 3. People who use either an iOS or Android smartphone 4. People who have 2 arms 5. Able and willing to provide informed consent and to adhere to study procedures. Exclusion Criteria: 1. Participants whose BP data submitted is \>180 mm Hg systolic OR \>120 mm Hg diastolic . 2. Participants with a self-reported known diagnosis of 1. atrial fibrillation 2. congestive heart failure 3. heart valve disease 4. pheochromocytoma 5. Raynaud's disease 6. arm lymphedema 3. Participants who take insulin 4. Participants who are on hemodialysis 5. Women who are self-reported to be pregnant 6. Participants whose arms shake uncontrollably or are paralyzed (cannot move) 7. Participants with upper arm circumference \<22 cm or \>42 cm 8. Participants with wrist circumference \>23cm 9. Participation in another interventional clinical study or use of investigational drugs in the last 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • Lindus Health

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.